Skip to main content
Login
Contact
Subscribe
ShopMarshallCountyOnline
Search form
Search
The Pilot News
Home
Forms
News
The Leader of Starke County
Culver Citizen
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Service Directory
Entertainment
Calendar
Friends To Follow
Special Sections
Talking About...
Photos
Videos
Games
Local Guide
Local Ads
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Catalyst Bio
(NQ:
CBIO
)
8.360
USD
-0.020 (-0.24%)
Official Closing Price
/ Updated:
5:16 PM EST, Feb 22, 2019
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
101,000
Open
8.390
Bid (Size)
7.790 (1)
Ask (Size)
9.000 (10)
Prev. Close
8.380
Today's Range
8.310 - 8.640
52wk Range
6.200 - 31.52
Shares Outstanding
11,935,169
Dividend Yield
N/A
Performance
YTD
+1.33%
+1.33%
1 Month
+7.87%
+7.87%
3 Month
-22.59%
-22.59%
6 Month
-24.34%
-24.34%
1 Year
-68.51%
-68.51%
Top News
More News
New Research: Key Drivers of Growth for Omega Healthcare Investors, Cinedigm, Cardiovascular, Allegiant Travel, Catalyst Biosciences, and ESCO Technologies — Factors of Influence, Major Initiatives an
February 19, 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Omega Healthcare...
Read More
from
GlobeNewswire News Releases
Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
February 08, 2019
Catalyst Biosciences, Inc. (NASDAQ: CBIO), presented updated interim data from the Phase 2/3 trial of subcutaneous prophylactic Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA)...
Read More
from
GlobeNewswire News Releases
More News
Read More
Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B
February 06, 2019
from
GlobeNewswire News Releases
Catalyst Biosciences to Present at the Annual BIO CEO & Investor Conference
February 05, 2019
from
GlobeNewswire News Releases
Catalyst Biosciences Announces Oral and Poster Presentations at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders
January 31, 2019
from
GlobeNewswire News Releases
Analysts Anticipate 10% Gains Ahead For IWN
February 14, 2019
category
ETFs
from
ETF Channel
Catalyst Biosciences Hosts Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs
December 18, 2018
from
GlobeNewswire News Releases
Notable Friday Option Activity: X, ABUS, CBIO
February 08, 2019
category
Stocks
from
Market News Video
Peek Under The Hood: IWN Has 21% Upside
January 09, 2019
category
ETFs
from
ETF Channel
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
December 24, 2018
category
KRR
,
Benzinga
,
Market News
, and 12 more.
from
Benzinga
5 Stocks To Watch For December 24, 2018
December 24, 2018
category
Market News
,
Benzinga
,
Stocks To Watch
, and 10 more.
from
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.